CXCR4 and familial pancreatic carcinoma: Recently, a nanobody molecule with bi-targeting on PD-L1 and CXCR4 were investigated in a pancreatic cancer since both of the targets are overexpressed in different cancers and play important roles in tumorigenesis [108].